A liquid aqueous formulation for the intranasal administration of apomorphine includes:(a) at least about 15 mg/ml of apomorphine； and(b) a solubilising agent selected from (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer)；(ii) at least one cyclodextrin； and(iii) at least one cyclodextrin together with chitosan.The formulations of the invention can be used in the treatment or management of Parkinson's disease and erectile dysfunction.
